This Plain Language Summary of Publication article (PLSP) from Future Oncology tested tirabrutinib, a new oral BTK inhibitor medication, in patients with primary central nervous system lymphoma (PCNSL) that had returned or wasn’t responding to treatment. The research was conducted in three phases: Phase I determined the optimal dose, Phase II evaluated treatment effectiveness, and a long-term follow-up tracked cancer progression over three years.

Visit the site using this link to read the article.

This PLSP is based on three articles called ‘Phase I/II study of tirabrutinib, a second-generation Bruton’s tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma’ published in Neuro-Oncology, ‘Karnofsky Performance Status and quality of life in patients with relapsed or refractory primary CNS lymphoma from a phase I/II study of tirabrutinib’ and ‘Three-year follow-up analysis of phase 1/2 study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma’ both published in Neuro-Oncology Advances. 

Visit Oxford Academic using the link to read the original article.

Visit Oxford Academic using the link to read the original article.

Visit Oxford Academic using the link to read the original article.